14
June
12:30pm - 1:00pm ET

Going global: Takeda CEO Christophe Weber talks about growth, R&D and the road ahead

Takeda has undergone a transformation in the 6 years since Christophe Weber was named CEO. Buyouts helped build the company into a top 15 R&D player, with global commercial and research capabilities. Now that the pandemic has begun to wane, what is Weber planning for the next 6 years as Takeda takes its place among the global giants?

Christophe Weber
Christophe Weber
CEO
Takeda
John Carroll
John Carroll
Editor & Founder
Endpoints News
1:00pm - 2:00pm ET

The new normal in R&D: What worked and what didn’t?

A year ago we invited a group of top R&D chiefs to discuss the impact the pandemic had on the field. Now we’re following up the discussion by concentrating on the new normal era ahead. What’s changed forever for R&D groups? What’s the central focus on the FDA front now and where are the greatest organizational challenges going forward as major organizations adapt to a new way of doing business with digital endpoints and more.

Panelists

Mathai Mammen
Mathai Mammen
Global Head, Janssen Research & Development
Johnson & Johnson
Sir Menelas (Mene) Pangalos
Sir Menelas (Mene) Pangalos
Executive Vice-President, R&D BioPharmaceuticals
AstraZeneca
John C. Reed
John C. Reed
EVP, Global Head of R&D
Sanofi
Pearl Huang
Pearl Huang
President & CEO
Cygnal Therapeutics
Mikael Dolsten
Mikael Dolsten
Chief Scientific Officer and President, Worldwide Research, Development and Medical
Pfizer
John Carroll
John Carroll (moderator)
Editor & Founder
Endpoints News
15
June
12:00pm - 1:00pm ET

The post-Covid pipeline takes shape. New vaccines and drugs during the mRNA revolution

The global pandemic has a long way to run globally. While the US outbreak may be on the verge of being contained, new variants and a multitude of pipeline problems is keeping this issue alive. As a result, we’ve already seen a host of followup drugs and vaccines enter human testing, and we’ll see lots more in the months ahead. We’ll talk to some of the leaders in the field, and get a better idea of how this can develop in late 2021 and throughout 2022.

Panelists

John Mascola
John Mascola
Director, Vaccine Research Center, NIAID
U.S. National Institutes of Health
George Scangos
George Scangos
President, CEO and Director
Vir Biotechnology
Joanne Liu
Joanne Liu
Professor, School of Population and Global Health
McGill University
Stephen Hoge
Stephen Hoge
President
Moderna
Andrew Plump
Andrew Plump
President of R&D
Takeda
Karen Flynn
Karen Flynn (presenting sponsor)
President, Biologics & Chief Commercial Officer
Catalent
John Carroll
John Carroll (moderator)
Editor & Founder
Endpoints News
1:00pm - 2:00pm ET

Manufacturing in the Covid era: Defining the new normal in manufacturing

The Covid-19 pandemic has challenged an increasingly global pharmaceutical supply chain as drugmakers have had to weather the storm of periodic lockdowns, chronic shortages and major delays at the FDA. Now, with the first phase of the pandemic over but variants still on the loose, what will the industry choose — whether practical or philosophical — to take away from the lockdown days? Our group of experts will share their thoughts on the new normal in manufacturing and when the industry expects to get running at full speed again.

Panelists

Martin Meeson
Martin Meeson
CEO
FUJIFILM Diosynth Biotechnologies
Steffen Lang, Ph.D.
Steffen Lang
Global Head of Technical Operations
Novartis
Amy DuRoss
Amy DuRoss
CEO and Co-founder
Vineti
Martin VanTrieste
Martin VanTrieste
President & Chief Executive Officer
Civica Rx
Ken Kent
Ken Kent (presenting sponsor)
SVP of Chemical, Development and Manufacturing Operations
Gilead
Kyle Blankenship
Kyle Blankenship (moderator)
Senior Editor
Endpoints News
16
June
12:00pm - 1:00pm ET

The new Biden administration — what’s ahead for biopharma?

Unexpectedly, Joe Biden barreled into the White House with a busy agenda, ramping up new regulations and laying out new policies that could have a major impact on the biopharma industry. Pricing, the regulatory environment at the FDA and FTC, and economic policy have all been pushed to the forefront. Let’s unpack what’s happening and what you should be watching out for.

Panelists

Andrew Lo
Andrew Lo
Dir., Financial Engineering Lab & Principal Investigator, Comp. Science & AI Lab
MIT
Vivek Ramaswamy
Vivek Ramaswamy
Founder and Executive Chairman
Roivant Sciences
Tahir Amin
Tahir Amin
Co-Founder, Co-Executive Director
I-MAK
Jeremy M. Levin
Jeremy M. Levin
Chairman of the Board of Directors and CEO
Ovid Therapeutics Inc
John Carroll
John Carroll (moderator)
Editor & Founder
Endpoints News
1:00pm - 1:30pm ET

Fireside chat with Robert Langer,
1 of 12 Institute Professors at MIT

As a scientist and an entrepreneur Robert Langer has helped launch more than 30 biotechs exploring a multitude of therapeutic arenas over the years — often involving his grad students. He helped found Moderna, which went on to trigger a revolution in vaccine development. And he continues to have his thumb on both the scientific and business side of the industry. We’ll be discussing both as Langer looks back — and forward.

Robert Langer
Robert Langer
Insitute Professor
Massachusetts Institute of Technology
John Carroll
John Carroll
Editor & Founder
Endpoints News

Register For the events

Monday, June 14
Tuesday, June 15
Wednesday, June 16

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please contact our support team.

SHARE ON